Market Overview

Atlas Energy Group, LLC Files Draft S-1 Registration Statement for a Continuous Public Offering by its Subsidiary, Atlas Growth Partners, L.P.


Atlas Energy Group, LLC (NYSE: ATLS) announced today that its privately held subsidiary, Atlas Growth Partners, L.P. ("AGP"), has filed a Registration Statement on Form S-1 with the Securities and Exchange Commission in connection with its proposed continuous public offering of common units representing limited partner interests in AGP. The common units will not initially be listed on any national securities exchanges. The offering of common units will be made only by means of a prospectus.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Atlas Energy Group, LLC (NYSE: ATLS) is a limited liability company which owns the following interests: all of the general partner interest, incentive distribution rights and an approximate 25% limited partner interest in its upstream oil & gas subsidiary, Atlas Resource Partners, L.P.; a general partner interest, incentive distribution rights and limited partner interests in Atlas Growth Partners, L.P.; and a general partner interest in Lightfoot Capital Partners, an entity that invests directly in energy-related businesses and assets. For more information, please visit our website at, or contact Investor Relations at

Posted-In: News Offerings Press Releases


Related Articles (ATLS)

View Comments and Join the Discussion!

The Bon-Ton Stores, Inc. Announces Real Estate Initiatives

Two New Studies Demonstrate the Long-Term Clinical Utility of Veracyte's Afirma Gene Expression Classifier in Safely Reducing Unnecessary Thyroid Surgeries